secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001390478-25-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Q3 net loss $6.8M ($0.06/sh); cash $44.3M plus $29.1M warrant proceeds in Oct
--------------------------------------------------------------------------------

- Net loss of $6.8M ($0.06 diluted EPS) vs $7.1M ($0.10) a year ago; nine-month loss $19.2M ($0.20).
- Cash and equivalents $44.3M at Sep 30, 2025; additional $29.1M net from warrant exercises in October.
- Phase 3 REGAL trial of GPS in AML CR2 final analysis expected by year-end 2025 (80 events).
- Phase 2 SLS009 in R/R AML data accepted for ASH 2025; trial in first-line AML to start Q1 2026.
- R&D expense $4.2M (down 5% YoY); G&A expense $2.9M (down 3% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047825000021/0001390478-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047825000021/sls-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001390478-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer